GlobeStar Therapeutics Corp - Quarter Report: 2018 March (Form 10-Q)

---

UNITED STATES

SECURITY AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

---

 

FORM 10-Q

 

---

 

(MARK ONE)

 

☒  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2018

 

or

 

☐  TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _________ to _________

 

Commission File Number: 333-170315

 

 

 

(Exact name of registrant as specified in its charter)

 

 

Registrant’s telephone number, including area code: 832-781-8521

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)

Yes ☐ No ☒

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. As of May 21, 2018, 54,584,067 shares of common stock are issued and outstanding.

---

TABLE OF CONTENTS

---

 

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain statements in this report contain or may contain forward-looking statements. These statements, identified by words such as “plan”, “anticipate”, “believe”, “estimate”, “should”, “expect” and similar expressions include our expectations and objectives regarding our future financial position, operating results and business strategy. These statements are subject to known and unknown risks, uncertainties and other factors, which may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward - looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous assumptions and other factors that could cause our actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, our ability to secure suitable financing to continue with our existing business or change our business and conclude a merger, acquisition or combination with a business prospect, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk, U.S. and global competition, and other factors. Most of these factors are difficult to predict accurately and are generally beyond our control. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Readers should carefully review this report in its entirety, including but not limited to our financial statements and the notes thereto and the risks described in our Annual Report on Form 10-K for the fiscal year ended September 30, 2017. We advise you to carefully review the reports and documents we file from time to time with the Securities and Exchange Commission (the “SEC”), particularly our quarterly reports on Form 10-Q and our current reports on Form 8-K. Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.

OTHER PERTINENT INFORMATION

When used in this report, the terms, “we,” the “Company,” “our,” and “us” refers to AngioSoma Inc., a Nevada corporation and its subsidiaries unless the context specifically indicates otherwise.

 

 

 

---

PART I — FINANCIAL INFORMATION

---

ITEM 1. FINANCIAL STATEMENTS

ANGIOSOMA INC.

CONSOLIDATED BALANCE SHEETS

MARCH 31, 2018 and SEPTEMBER 30, 2017

(UNAUDITED)

The accompanying notes are an integral part of these unaudited consolidated financial statements.

ANGIOSOMA INC.

CONSOLIDATED STATEMENT OF OPERATIONS

FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2018 AND 2017

(UNAUDITED)

		Three Months Ended March 31,								Six Months Ended March 31,
		2018				2017				2018				2017
REVENUE		$	-							$	-
OPERATING EXPENSES
General and administrative expenses			41,724				119,863				170,419				356,702
Total operating expenses			41,724				119,863				170,419				356,702
LOSS FROM OPERATIONS			(41,724	)			(119,863	)			(170,419	)			(356,702	)
OTHER INCOME (EXPENSE)
Oil lease income			5,531				-				5,531				-
Loss on conversion of preferred stock			-				-				(7,250	)			-
Loss on conversion of debt			-				-				(328,200	)			-
Interest expense			(4,019	)			(75,540	)			(5,224	)			(156,114	)
NET LOSS		$	(40,212	)		$	(195,403	)		$	(505,562	)		$	(512,816	)
NET LOSS PER COMMON SHARE - Basic and diluted		$	(0.00	)		$	(0.01	)		$	(0.01	)		$	(0.01	)
WEIGHTED AVERAGE SHARES OUTSTANDING			54,056,289				37,535,178				52,691,759				36,881,169

The accompanying notes are an integral part of these unaudited consolidated financial statements.

ANGIOSOMA INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2018 AND 2017

(UNAUDITED)

		Three Months Ended March 31,								Six Months Ended March 31,
		2018				2017				2018				2017
NET LOSS		$	(40,212	)		$	(195,403	)		$	(505,562	)		$	(512,816	)
Change in fair value of AFS securities		$	1,941			$	-				3,882				2,911
COMPREHENSIVE LOSS		$	(38,271	)		$	(195,403	)		$	(501,680	)		$	(509,905	)

The accompanying notes are an integral part of these unaudited consolidated financial statements.

ANGIOSOMA INC.

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE SIX MONTHS ENDED MARCH 31, 2018

(UNAUDITED)

																																																						Accumulated
										Series A								Series B								Series D								Series E								Series F								Additional				Other								Total
		Common stock								Preferred Stock								Preferred Stock								Preferred Stock								Preferred Stock								Preferred Stock								paid-in				Comprehensive				Accumulated				Equity
		Shares				Par				Shares				Amount				Shares				Amount				Shares				Amount				Shares				Amount				Shares				Amount				capital				Income				Deficit				(Deficit)
Balance, September 30, 2017			45,584,067			$	45,584				5,000,000			$	2,990,535				30,000			$	30				509,888			$	510				1,000,000			$	1,000				471,975			$	472			$	1,520,658			$	(970	)		$	(5,181,794	)		$	(623,975	)
Common stock issued for conversion of convertible note payable			6,000,000				6,000				-				-				-				-				-				-				-				-				-				-				(6,000	)			-				-				-
Common stock issued for conversion of Series B Preferred Stock			500,000				500				-				-				(30,000	)			(30	)			-				-				-				-				-				-				6,780				-				-				7,250
Loss on conversion of debt			-				-				-				-				-				-				-				-				-				-				-				-				328,200				-								328,200
Common stock issued for conversion of Series F Preferred Stock			2,500,000				2,500				-				-				-				-				-				-				-				-				(25,000	)			(25	)			(2,475	)			-				-				-
Discount on convertible note payable			-				-				-				-				-				-				-				-				-				-				-				-				4,253				-				-				4,253
Net loss			-				-				-				-				-				-				-				-				-				-				-				-								-				(505,562	)			(505,562	)
Other comprehensive loss			-				-				-				-				-				-				-				-				-				-				-				-				-				3,882				-				3,882
Balance, March 31, 2018			54,584,067			$	54,584				5,000,000			$	2,990,535				-			$	-				509,888			$	510				1,000,000			$	1,000				446,975			$	447			$	1,851,416				2,912			$	(5,687,356	)		$	(785,952	)

The accompanying notes are an integral part of these unaudited consolidated financial statements.

ANGIOSOMA INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED MARCH 31, 2018 AND 2017

(UNAUDITED)

		Six Months Ended
		March 31,
		2018				2017
CASH FLOW FROM OPERATING ACTIVITIES:
Net loss		$	(505,562	)			(512,816	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation			-				283,770
Amortization of discount on convertible note payable			1,344				90,723
Loss on conversion of preferred stock			7,250				-
Loss on conversion of debt			328,200				-
Changes in operating assets and liabilities
Prepaid expenses			(7,306	)			-
Accounts payable and accrued liabilities			7,844				(24,578	)
Accounts payable to related party			120,106				61,935
Accrued interest payable			574				62,650
NET CASH USED IN OPERATING ACTIVITIES			(47,550	)			(38,316	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from advances			-				10,000
Proceeds from convertible notes payable			100,000				30,000
NET CASH PROVIDED BY FINANCING ACTIVITIES			100,000				40,000
NET INCREASE IN CASH			52,450				1,684
Cash at beginning of period			14,100				5,845
Cash at end of period		$	66,550			$	7,529

Cash paid during the period for:
Interest		$	-			$	-
Taxes		$	-			$	-
Noncash investing and financing transactions:
Discount issuance on convertible debt		$	4,253			$	-
Conversion of convertible notes payable into common stock		$	6,000			$	6,618
Change in fair value of available-for-sale securities		$	3,882			$	2,911
Preferred stock converted to common stock		$	3,000			$	-

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

ANGIOSOMA INC.

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2018

Note 1. General Organization and Business

AngioSoma, Inc., a Nevada corporation (“AngioSoma” or the “Company”), is a clinical stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (PAD).

AngioSoma is developing its lead product, a drug candidate called Liprostin^TM for the treatment of peripheral artery disease, or PAD, which has completed FDA Phase I and three Phase II clinical trials. We are in discussions with several contract research organizations for completion of our FDA protocol for Phase III and submission of our new drug application for marketing in the US and its territories.

The Company was incorporated on April 29, 2016. The Company’s year-end is September 30.

Note 2. Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the six months ended March 31, 2018, the Company had a net loss of $505,562 and negative cash flow from operating activities of $47,550. As of March 31, 2018, the Company had negative working capital of $658,415. Management does not anticipate having positive cash flow from operations in the near future.

These factors raise a substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

The Company does not have the resources at this time to repay its credit and debt obligations, make any payments in the form of dividends to its shareholders or fully implement its business plan. Without additional capital, the Company will not be able to remain in business.

Management has plans to address the Company’s financial situation as follows:

In the near term, management plans to continue to focus on raising the funds necessary to implement the Company’s business plan. Management will continue to seek out debt financing to obtain the capital required to meet the Company’s financial obligations. There is no assurance, however, that lenders will continue to advance capital to the Company or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raise doubts about the Company’s ability to continue as a going concern.

In the long term, management believes that the Company’s projects and initiatives will be successful and will provide cash flow to the Company, which will be used to finance the Company’s future growth. However, there can be no assurances that the Company’s planned activities will be successful, or that the Company will ultimately attain profitability. The Company’s long-term viability depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation of its business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to sustain its operations.

Note 3. Summary of Significant Accounting Policies

Interim Financial Statements

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X. The results of operations for the six months ended March 31, 2018 are not necessarily indicative of the results to be expected for the full fiscal year ending September 30, 2018.

Consolidated Financial Statements

The consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries, AngioSoma Research, LLC, First Titan Energy, LLC and First Titan Technical, LLC from the date of their formations or acquisition. Significant intercompany transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Fair Value of Financial Instruments

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization.

FASB Accounting Standards Codification (ASC) 820 Fair Value Measurements and Disclosures (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2018. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts receivable, other current assets, accounts payable, and accrued expenses. The fair value of the Company’s notes payable is estimated based on current rates that would be available for debt of similar terms that is not significantly different from its stated value.

The following table presents assets that were measured and recognized at fair value as of March 31, 2018 and the period then ended on a recurring and nonrecurring basis:

The following table presents assets that were measured and recognized at fair value as of September 30, 2017 and the period then ended on a recurring and nonrecurring basis:

Commitments and Contingencies

The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. There are no known commitments or contingencies as of March 31, 2018.

Recently Issued Accounting Pronouncements

We have reviewed the FASB issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration.

Subsequent events

The Company follows the guidance in Section 855-10-50 of the FASB Accounting Standards Codification for the disclosure of subsequent events. The Company will evaluate subsequent events through the date when the financial statements were issued. Pursuant to ASU 2010-09 of the FASB Accounting Standards Codification, the Company as an SEC filer considers its financial statements issued when they are widely distributed to users, such as through filing them on EDGAR.

Note 4. Advances

As of March 31, 2018 and September 30, 2017, the Company had non-interest bearing advances payable to third parties of $59,650. These advances are payable on demand.

Note 5. Convertible Notes Payable

Convertible notes payable consisted of the following at March 31, 2018 and September 30, 2017:

 

All principal along with accrued interest is payable on the maturity date. The notes are convertible into common stock at the option of the holder. The holder of the notes cannot convert the notes into shares of common stock if that conversion would result in the holder owning more than 4.9% of the outstanding stock of the Company.

 

As of March 31, 2018 and 2017, accrued interest on notes payable was $222,477 and $160,255, respectively.

Conversions of Notes Payable to Common Stock

During six months ended March 31, 2018, the holders of the Convertible Note Payable dated June 30, 2015 elected to convert principal of $0 into 6,000,000 shares of common stock. A loss of $328,200 was recognized on the conversions as they occurred after all debt had been fully converted as of September 30, 2017. This is recorded under additional paid in capital.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

AngioSoma is a clinical stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (PAD).

AngioSoma is developing its lead product, a drug candidate called Liprostin^TM for the treatment of peripheral artery disease, or PAD, which has completed FDA Phase I and three Phase II clinical trials. We are in discussions with several contract research organizations for completion of our FDA protocol for Phase III and submission of our new drug application for marketing in the US and its territories.

Critical Accounting Policies

We prepare our consolidated financial statements in conformity with GAAP, which requires management to make certain estimates and apply judgments. We base our estimates and judgments on historical experience, current trends, and other factors that management believes to be important at the time the condensed consolidated financial statements are prepared. We regularly review our accounting policies, and how they are applied and disclosed in our condensed consolidated financial statements.

While we believe that the historical experience, current trends and other factors considered support the preparation of our condensed consolidated financial statements in conformity with GAAP, actual results could differ from our estimates and such differences could be material.

Results of Operations

Three Months Ended March 31, 2018 Compared to the Three Months Ended March 31, 2017

Revenue.  We had no revenue from operations for the three months ended March 31, 2018 and 2017.

General and administrative expense.  We recognized general and administrative expense of $41,724 for the three months ended March 31, 2018 compared to $119,863 for the comparable period of 2017. The decrease in general and administrative expense was related to a decrease in consulting fees during the period.

Oil lease income.  We recognized other income of $5,531 related to an oil lease for the three months ended March 31, 2018 compared to $0 for the comparable period of 2017.

 

Interest expense.  We recognized interest expense of $4,019 for the three months ended March 31, 2018 compared to $75,540 for the comparable period of 2017. The decrease was primarily related to most convertible notes being converted into preferred and common stock during the year ended September 30, 2017.

Net loss.  We recognized a net loss of $40,212 for the three months ended March 31, 2018 and $195,403 for the three months ended March 31, 2017. The decrease in our net loss was a result of the loss on conversion of debt and preferred stock discussed in note 7.

Six Months Ended March 31, 2018 Compared to the Six Months Ended March 31, 2017

Revenue.  We had no revenue from operations for the six months ended March 31, 2018 and 2017.

General and administrative expense.  We recognized general and administrative expense of $170,419 for the six months ended March 31, 2018 compared to $356,702 for the comparable period of 2017. The decrease in general and administrative expense was related to a decrease in consulting fees.

 

Interest expense.  We recognized interest expense of $5,224 for the six months ended March 31, 2018 compared to $156,114 for the comparable period of 2017. The decrease was primarily related to most convertible notes being converted into preferred and common stock during the year ended September 30, 2017.

Additional Financing

Additional financing is required to continue operations. Although actively searching for available capital, the Company does not have any current arrangements for additional outside sources of financing and cannot provide any assurance that such financing will be available.

Off Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable to a smaller reporting company.

ITEM 4. CONTROLS AND PROCEDURES

Management’s Report on Internal Control over Financial Reporting

We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March 31, 2018. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of March 31, 2018, our disclosure controls and procedures were not effective to ensure that information required to be disclosed in reports filed by us under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Our management, including our principal executive officer and principal financial officer, who is the same person, does not expect that our disclosure controls and procedures or our internal controls will prevent all error or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

Change in Internal Controls Over Financial Reporting

There was no change in our internal controls over financial reporting that occurred during the period covered by this report, which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

 

---

PART II — OTHER INFORMATION

---

ITEM 1. LEGAL PROCEEDINGS

We know of no material, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholder are an adverse party or has a material interest adverse to us.

ITEM 1A. RISK FACTORS

Not applicable to a smaller reporting company.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Set forth below is information regarding the securities sold during the quarter ended March 31, 2018 that were not registered under the Securities Act:

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

The Company has not defaulted upon senior securities.

ITEM 4. MINE SAFETY DISCLOSURES

This item is not applicable to smaller reporting companies.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.